X25d3a106.8a9a.4285.9b02.1ba01b7a9ad2
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.630
- INFLAMMATORY_RESPONSE+0.570
- IL6_JAK_STAT3_SIGNALING+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ALLOGRAFT_REJECTION+0.500
- ANGIOGENESIS+0.480
- APICAL_SURFACE+0.460
- COAGULATION+0.430
- COMPLEMENT+0.410
- IL2_STAT5_SIGNALING+0.410
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- MYC_TARGETS_V1-0.420
- DNA_REPAIR-0.390
- PROTEIN_SECRETION-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.290
- E2F_TARGETS-0.260
- GLYCOLYSIS-0.220
- MTORC1_SIGNALING-0.190
- PEROXISOME-0.180
- CHOLESTEROL_HOMEOSTASIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AD9G-TTM3-A-1-1-R-A542-39 | — | D | 0.927 |
| 2 | BS_G1Y281HX | Neuroblastoma | — | 0.925 |
| 3 | MNG721 | — | — | 0.921 |
| 4 | X46c96724.b37b.46c0.9cae.a4a1a5604bf0 | — | cohortMD2 | 0.918 |
| 5 | MDT-AP-1128 | Med | Medulloblastoma | 0.914 |
| 6 | BS_Z28VKGNS | Neurofibroma | — | 0.909 |
| 7 | TCGA-85-8049-01A-11R-2247-07 | — | cohortSQ1 | 0.908 |
| 8 | BS_TA9WP4TH | Med | Medulloblastoma | 0.908 |
| 9 | C3L-02170 | — | cohortMD2 | 0.905 |
| 10 | SRR12202494 | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.630 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.460 | Temsirolimus | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |